The FDA and NIH are pushing for a reduction in animal testing, promoting the use of organ-on-chip systems as validated new approach methodologies (NAMs). This shift is crucial for developers aiming to integrate these technologies into regulatory frameworks, though challenges remain regarding validation standards and adoption rates. Developers like Emulate and CN Bio are enhancing their platforms to meet growing demand from pharmaceutical companies and academic institutions.
Read the full article at Genetic Engineering News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
3
Ali NematiWritten by Ali
